Therapeutic Group

Indication Dosage

Imatinib Mesylate is prescribed to treat certain types of leukemia and other rare blood disorders, as well as specific gastrointestinal stromal tumors (GISTs) in patients who require this targeted therapy.

Treatment Of Chronic Myeloid Leukaemia In Chronic Phase After Failure With Interferon Alfa: 

• Adult: 400 Mg Once Daily, Increased If Necessary Up To 800 Mg Daily In 2 Divided Doses

Treatment Of Chronic Myeloid Leukaemia In Accelerated Phase, Or In Blast Crisis: 

• Adult: 600 Mg Once Daily, Then Increased If Necessary Up To 800 Mg Daily In 2 Divided Doses
• Children Over 3 Yrs: 260 Mg/m2 Daily As A Single Dose Or In Two Divided Doses; Max 400 Mg Daily; In Advanced Phase:340 Mg/m2 Daily As A Single Dose Or In Two Divided Doses; Max 600 Mg Daily. 

Treatment Of Newly Diagnosed Acute Lymphoblastic Leukaemia (in Combination With Other Chemotherapy), Monotherapy For Relapsed Or Refractory Acute Lymphoblastic Leukaemia: 

• Adult: 600 Mg Once Daily 

Treatment Of C-kit (cd117)-positive Unresectable Or Metastatic Malignant Gastro-intestinal Stromal Tumours (gist), Adjuvant Treatment Following Resection Of C-kit (cd117)-positive Gist, In Patients At Significant Risk Of Relapse, Treatment Of myelodysplastic/myeloproliferative Diseases Associated with Platelet-derived Growth Factor Receptor Gene rearrangement: 

• Adult: 400 Mg Once Daily 

Treatment Of Unresectable Dermatofibrosarcoma Protuberans, Recurrent Or Metastatic Dermatofibrosarcoma Protuberans, When Surgery Is Not Possible: 

• Adult: 800 Mg Daily In 2 Divided Doses 

Treatment Of Advanced Hypereosinophilic Syndrome And Chronic Eosinophilic Leukaemia: 

• Adult: 100-400 Mg Once Daily

Content

Pregnancy

Positive Evidence Of Risk: Avoid

Stability

Contra Indications

Precautions

Lactation

Side Effects